Tysabri Risk Plan Could Be Implemented In Weeks, Biogen Predicts
Executive Summary
Biogen Idec expects to implement its risk management plan for multiple sclerosis therapy Tysabri in a matter of weeks following the product's return to market, the company said one day after the FDA advisory committee meeting on the product